Table 1

Patient demographics, covariates, and treatment outcomes in pregnant and nonpregnant women with uncomplicated malariaa

CharacteristicPregnant womenNonpregnant women
Total no. of patients2424
Total no. of piperaquine samples749740
Total dose of piperaquine base (mg/kg)30.8 (28.3–33.8)29.0 (27.7–33.8)
Total no. of dihydroartemisinin samples480480
Total dose of dihydroartemisinin (mg/kg)6.67 (6.12–7.32)6.28 (6.00–7.32)
Continuous and categorical covariates at admission
    Age (yr)25 (18–43)27.5 (18–45)
    Body wt (kg)51 (36–58)48 (37–78)
    Axillary temp at admission (°C)37.6 (36.2–39.8)37.5 (36.7–39.3)
    Parasitemia at admission (no. of parasites/μl)6,780 (96.0–177,000)9,670 (32.0–136,000)
    Systolic blood pressure (mm Hg)100 (90–130)105 (90–130)
    Diastolic blood pressure (mm Hg)60 (40–70)70 (60–90)
    Hematocrit (%)30.5 (24–38)35 (26–43)
    Smokers (%)12.512.5
    Estimated gestational age (wk)25.3 (13.1–33.4)NAb
    Time to delivery (days)93 (28–180)NA
Treatment outcome by day 63
    Parasite clearance time (days)2 (1–4)2 (1–4)
    % (no. of patients with no parasite reappearance/total no. of patients)45.8 (11/24)54.5 (12/22)c
    % (no. of patients with recrudescent falciparum malaria/total no. of patients)d4.17 (1/24)4.55 (1/22)c
    Time (days) to recrudescent falciparum malariad3121
    % (no. of patients with new P. falciparum infection/total no. of patients)d8.33 (2/24)4.55 (1/22)c
    Time (days) to new P. falciparum infectiond38.5 (35–42)56
    % (no. of patients with new P. vivax infection/total no. of patients)41.7 (10/24)36.4 (8/22)c
    Time (days) to new P. vivax infection52.5 (28–63)49 (35–63)
    No. of patients lost during follow-up2
    Time (days) to loss to follow-up31.5 (14–49)
  • a All values are given as median (range) unless otherwise specified.

  • b NA, not applicable.

  • c Two patients were lost during follow-up.

  • d As confirmed by PCR.